Brief: BioNtech And Autolus Announce Strategic CAR-T Cell Therapy Collaboration To Advance Pipeline And Expand Late-Stage Programs

Autolus Therapeutics

08/02/2024 11:18

Feb 8 (Reuters) - BioNTech SE  22UAy.DE :
    * BIONTECH AND AUTOLUS ANNOUNCE STRATEGIC CAR-T CELL THERAPY
COLLABORATION TO ADVANCE PIPELINE AND EXPAND LATE-STAGE PROGRAMS
    * BIONTECH SE - BIONTECH HAS CO-COMMERCIALIZATION OPTIONS
FOR
AUTOLUS' AUTO1/22 AND AUTO6NG PROGRAMS
    * BIONTECH SE: BIONTECH AGREES TO INVEST $200 MILLION IN
AUTOLUS
    * BIONTECH SE - BIONTECH AGREES TO INVEST $200 MILLION IN
AUTOLUS
    * BIONTECH SE - UNDER TERMS OF LICENSE AND OPTION AGREEMENT,
BIONTECH WILL MAKE A CASH PAYMENT OF $50 MILLION
    * BIONTECH SE - UNDER AGREEMENT BIONTECH IS ELIGIBLE TO
RECEIVE AN
UP TO MID-SINGLE DIGIT ROYALTY ON OBE-CEL NET SALES
    * BIONTECH SE - UNDER AGREEMENT AUTOLUS WILL RETAIN FULL
RIGHTS TO
AND CONTROL OF DEVELOPMENT AND COMMERCIALIZATION OF OBE-CEL
    * BIONTECH - HAS OPTION TO ACCESS AUTOLUS' COMMERCIAL &
CLINICAL
SITE NETWORK, MANUFACTURING CAPACITIES IN U.K. AND COMMERCIAL
SUPPLY INFRASTRUCTURE

Source text for Eikon:  ID:nGNX7YvCsf 
Further company coverage:  22UAy.DE